NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its Phase 2a SYNAPSE-CMT study evaluating ignaseclant (formerly known as NMD670) in patients living with Charcot-Marie-Tooth disease (CMT) types 1 or 2 has been accepted for a late-breaking oral presentation at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held in Orlando, Florida from March 8-11, 2026.
Presentation details are below:
Date: Wednesday, March 11, 2026
Start Time: 2:15 PM ET
Location: Hilton Orlando, Orlando, FL
Room Name: Florida 4
Presentation Name: Efficacy and safety of ignaseclant in adults with Charcot-Marie-Tooth Disease: Top Line Results of a Phase 2a study
Presenter: W. David Arnold, M.D., Executive Director of the NextGen Precision Health Initiative,
Professor of Physical Medicine and Rehabilitation, Co-Director of Tom and Anne Smith MD/PhD Program, University of Missouri School of Medicine
The Muscular Dystrophy Association (MDA) has announced the agenda for its 2026 MDA Clinical & Scientific Conference and the focus for this year’s Conference, the nonprofit says, is on “groundbreaking research and clinical achievements.” Over 2,000 participants from over 40 countries are expected to attend.
Ignaseclant is an investigational first-in-class small molecule inhibitor of the skeletal muscle-specific chloride ion channel 1 (CIC-1). There are currently no FDA-approved therapies for the treatment of CMT.
On 3 February 2026, NMD Pharma announced topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2.
Contact
NMD Pharma A/S
Dan Brennan, SVP Corporate and Commercial Strategy E-mail: contact@nmdpharma.com
ICR Healthcare
Mary-Jane Elliott / Ashley Tapp / Lindsey Neville
E-mail: NMDPharma@icrhealthcare.com